Amylyx Pharmaceuticals, Inc.
Every calculator, already run for AMLX
Open the full toolkit →You have the numbers on AMLX. Get the argument.
A written report on which of these readings actually decide the outcome for Amylyx Pharmaceuticals, Inc., what has to stay true for the price to work, and the specific thing that would break it. The first one is free.
Key market data
Analyst consensus
12 analysts covering AMLXAnalyst Price Target Disagreement for Amylyx Pharmaceuticals, Inc.
Wall Street's bull case implies +14% from the current price; the bear case implies -43%. A 57% spread signals high analyst disagreement — run your own DCF to anchor on fundamentals rather than street consensus.
Ownership & short interest
Insider Trading Activity for AMLX
| Insider | Role | Type | Shares | Price | Value | Date | Filing |
|---|---|---|---|---|---|---|---|
About Amylyx Pharmaceuticals, Inc.
Amylyx Pharmaceuticals, Inc., a clinical-stage pharmaceutical company, engages in the discovery and development of treatment options for neurodegenerative diseases and endocrine conditions in the United States. It provides Avexitide, an investigational, first-in-class glucagon-like peptide-1, or GLP-1 receptor antagonist, which is in phase 3 clinical trial to treat post-bariatric hypoglycemia and congenital hyperinsulinism. The company also develops AMX0035, an oral, fixed-dose combination of sodium phenylbutyrate and taurursodiol which is phase 2 clinical trial for the treatment of wolfram syndrome, as well as in phase 2b/3 clinical trial to treat progressive supranuclear palsy; AMX0114, wh…
AMLX — frequently asked
Is AMLX a buy right now?
Wall Street's consensus rating on Amylyx Pharmaceuticals, Inc. is Strong Buy across 12 analysts, with a mean price target of $28.09 (-20% vs. the current $35.11). Ratings are a starting point — run the DCF and check the financial-health readings above before deciding.
When is AMLX's next earnings date?
Amylyx Pharmaceuticals, Inc. is next scheduled to report earnings around Nov 5, 2026. A full AMLX research report from Basis Report covers the setup into that print — estimates, the beat/miss record, and what would move the thesis.
What is the analyst price target disagreement for Amylyx Pharmaceuticals, Inc.?
Analysts covering Amylyx Pharmaceuticals, Inc. (AMLX) range from a bear-case target of $20.00 to a bull-case high of $40.00, with a mean consensus target of $28.09 across 11 analysts. The spread of $20.00 (57% of the current price) indicates high disagreement on the outlook. Run the DCF calculator to build your own estimate independent of street consensus.
Compare Amylyx Pharmaceuticals, Inc. against related stocks
Explore additional stock overview pages and jump directly into full report generation for each symbol.
Sector peers
Most-followed names in the same sector.
Nearby tickers
Additional public equities from our tracked universe.
Market leaders
Large-cap symbols investors frequently compare.
Investor Guides For Amylyx Pharmaceuticals, Inc.
Start with the evergreen guides that matter most for Healthcare, then move back into the ticker page when you want to pressure-test the framework on a live name.
Generate your full AMLX research report
DCF model, five-year financials, moat assessment, a BUY/HOLD/SELL rating, and the risks that matter — on Amylyx Pharmaceuticals, Inc., in minutes. 3 free reports included with every account — no credit card required.